This review uncovers the involvement of PARPs in liver diseases, finding strong links to fibrosis and hepatocellular carcinoma, suggesting potential for targeted therapies.
Poly(ADP-ribose) polymerases (PARPs) comprise a family of 17 enzymes were initially identified for their essential roles in DNA damage repair and maintenance of genomic stability. Emerging evidence has unveiled their critical involvement in various liver diseases, including viral hepatitis, metabolic disorders, fibrosis, and hepatocellular carcinoma. This review summarizes PARPs’ roles in liver diseases and the evidence supporting PARP inhibitor therapy.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: